Search results for "Reti"

showing 10 items of 16256 documents

Chemistry, Pharmacodynamics, and Pharmacokinetics of NSAIDs

2016

Numerous chemically different entities are clustered under the label of nonsteroidal anti-inflammatory drugs (NSAIDs). They share the ability to inhibit prostanoid synthesis by blocking the activity of the cyclooxygenase enzymes and, as a consequence, to exert anti-inflammatory, analgesic, and antipyretic effects. On the other hand, by hindering the housekeeping roles of prostaglandins, they also deteriorate the gastrointestinal mucosal barrier and the renal and endothelial hemodynamic regulation. The present chapter compiles available pharmacokinetic and pharmacodynamic data that may help to understand the different therapeutic profiles reported for particular agents.

0301 basic medicineNonsteroidalbiologyChemistryAnalgesicHemodynamic regulation030204 cardiovascular system & hematologyPharmacologyProstanoid synthesis03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinePharmacokineticsPharmacodynamicsbiology.proteinmedicineCyclooxygenaseAntipyreticmedicine.drug
researchProduct

2018

Inflammation has been described as an initiator event of major diseases with significant impacts in terms of public health including in cardiovascular disease, autoimmune disorders, eye diseases, age-related diseases, and the occurrence of cancers. A preventive action to reduce the key processes leading to inflammation could be an advantageous approach to reducing these associated pathologies. Many studies have reported the value of polyphenols such as resveratrol in counteracting pro-inflammatory cytokines. We have previously shown the potential of red wine extract (RWE) and the value of its qualitative and quantitative polyphenolic composition to prevent the carcinogenesis process. In thi…

0301 basic medicineNutrition and DieteticsActivator (genetics)medicine.drug_classInterleukinSignal transducing adaptor proteinInflammasomeInflammationPharmacologyResveratrolAnti-inflammatory3. Good health03 medical and health scienceschemistry.chemical_compound030104 developmental biologychemistrymedicineSecretionmedicine.symptomFood Sciencemedicine.drugNutrients
researchProduct

A large-scale screening for the taiga tick, Ixodes persulcatus, and the meadow tick, Dermacentor reticulatus, in southern Scandinavia, 2016

2019

Abstract The taiga tick, Ixodes persulcatus, has previously been limited to eastern Europe and northern Asia, but recently its range has expanded to Finland and northern Sweden. The species is of medical importance, as it, along with a string of other pathogens, may carry the Siberian and Far Eastern subtypes of tick-borne encephalitis virus. These subtypes appear to cause more severe disease, with higher fatality rates than the central European subtype. Until recently, the meadow tick, Dermacentor reticulatus, has been absent from Scandinavia, but has now been detected in Denmark, Norway and Sweden. Dermacentor reticulatus carries, along with other pathogens, Babesia canis and Rickettsia r…

0301 basic medicineNymphmeadow tickDermacentor reticulatus030231 tropical medicineZoologyIxodes persulcatusIxodes persulcatusTickScandinavian and Nordic CountriesSiberian and Far Eastern tick-borne encephalitisTaiga ticklcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicineDogsDermacentor reticulatusBabesiosisparasitic diseasesmedicineAnimalslcsh:RC109-216NymphLetter to the Editorrange expansionDermacentorSwedenTick-borne diseasebiologyIxodesNorwayTick-borne encephalitisArthropod VectorsBabesiosismedicine.diseasebiology.organism_classificationGrasslandTick Infestations030104 developmental biologyInfectious DiseasesTick-Borne DiseasesEpidemiological MonitoringBabesia canissouthern ScandinaviaParasitologyAnimal DistributionEncephalitis Tick-BorneParasites & Vectors
researchProduct

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

2019

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterat…

0301 basic medicineOncologyIndolesLung Neoplasmsnon-small cell lung cancer (NSCLC)Reviewlcsh:Chemistrychemistry.chemical_compoundIdiopathic pulmonary fibrosis0302 clinical medicineCarcinoma Non-Small-Cell LungMyofibroblastslcsh:QH301-705.5SpectroscopyGeneral MedicinePirfenidonerespiratory systemComputer Science Applicationsnon-small cell lung cancer (NSCLC)030220 oncology & carcinogenesisNintedanibidiopathic pulmonary fibrosis (IPF)Myofibroblastmedicine.drugmedicine.medical_specialtyPyridonesAntineoplastic AgentsCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicineAnimalsHumansPhysical and Theoretical ChemistryLung cancerMolecular Biologylung cancer (LC)business.industryOrganic ChemistryMesenchymal stem cellmedicine.diseaseIdiopathic Pulmonary Fibrosisrespiratory tract diseases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryConcomitantbusinessInternational Journal of Molecular Sciences
researchProduct

Prognosis and cure of long-term cancer survivors: A population-based estimation.

2019

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.…

0301 basic medicineOncologyMaleCancer ResearchTime FactorsSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineCancer SurvivorsProstateNeoplasmsThyroid cancerOriginal Researcheducation.field_of_studyRelative survivalMortality rateMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosispopulation-based cancer registriemedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesiscancer cure Italy population-based cancer registries prevalence survivalFemaleCancer PreventionAdultmedicine.medical_specialtypopulation-based cancer registriesAdolescentPopulationprevalenceSocio-culturalelcsh:RC254-282survival03 medical and health sciencesYoung AdultLife ExpectancyInternal medicinemedicinepopulation‐based cancer registriesHumansRadiology Nuclear Medicine and imagingcancer cureeducationAgedEstimationbusiness.industryCancerModels Theoreticalmedicine.disease030104 developmental biologyLife expectancycancer cure; Italy; population-based cancer registries; prevalence; survivalbusinessCancer medicine
researchProduct

Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report

2021

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a …

0301 basic medicineOncologyMaleCase ReportAutoimmunityPembrolizumabPD1-checkpoint inhibitorsmedicine.disease_causeAutoimmunity0302 clinical medicineAntineoplastic Agents ImmunologicalBiology (General)HLA AntigenMyositiPD1-checkpoint inhibitorSpectroscopyMyositisGeneral MedicineComputer Science ApplicationsMyasthenia GraviChemistryPyridostigmineurothelial cancer030220 oncology & carcinogenesisUrinary Bladder NeoplasmClass-I/II HLAMyastheniamedicine.drugHumanmedicine.medical_specialtyQH301-705.5PrognosiHuman leukocyte antigenAntibodies Monoclonal HumanizedCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicinePhysical and Theoretical ChemistryAdverse effectMolecular BiologyQD1-999Agedbusiness.industryOrganic ChemistryCancermedicine.diseaseDiscontinuation030104 developmental biologybusiness
researchProduct

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

2017

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”,…

0301 basic medicineOncologyPathologyAngiogenesisCarcinosarcomas epigenetics genetics immunotherapy uterine cancer.medicine.medical_treatmentReviewEpigenesis Geneticlcsh:Chemistry0302 clinical medicineCarcinosarcomaAntibodies BispecificCarcinosarcomas Epigenetics Genetics Immunotherapy Uterine cancerMedicinegeneticsMolecular Targeted Therapylcsh:QH301-705.5Human Epidermal Growth Factor Receptor 2SpectroscopyNeovascularization PathologicGeneral MedicineEpithelial Cell Adhesion MoleculePrognosisComputer Science ApplicationsErbB ReceptorsSurvival Rate030220 oncology & carcinogenesisUterine NeoplasmsFemaleImmunotherapymedicine.medical_specialtyPoor prognosisMixed Tumor MullerianCatalysisuterine cancerInorganic Chemistry03 medical and health sciencesCancer stem cellInternal medicineBiomarkers TumorHumansTarget therapyPhysical and Theoretical ChemistrycarcinosarcomasMolecular BiologySurvival rateChemotherapyepigeneticsbusiness.industryOrganic ChemistryImmunotherapy030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessInternational Journal of Molecular Sciences
researchProduct

Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial)

2017

IntroductionRecent studies suggest that endoplasmic reticulum stress may play a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS) through an altered regulation of the proteostasis, the cellular pathway-balancing protein synthesis and degradation. A key mechanism is thought to be the dephosphorylation of eIF2α, a factor involved in the initiation of protein translation. Guanabenz is an alpha-2-adrenergic receptor agonist safely used in past to treat mild hypertension and is now an orphan drug. A pharmacological action recently discovered is its ability to modulate the synthesis of proteins by the activation of translational factors preventing misfolded protein accumula…

0301 basic medicineOncologyPathologyamyotrophic lateral sclerosisamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; adrenergic alpha-2 receptor agonist s; age of onset; amyotrophic lateral sclerosis; disease progression; double-blind method; endoplasmic reticulum stress; guanabenz; humans; italy; medical futility; neuroprotective agents; proteostasis deficienciesamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Medicine (all)randomized clinical trial guanabenzHelsinki declaration0302 clinical medicineProtocolAdrenergic alpha-2 Receptor Agonists1506Amyotrophic lateral sclerosisAge of OnsetGuanabenzMedicine (all)amyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein responseNeurodegenerationamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response;amyotrophic lateral sclerosis; guanabenz; motor neurone disease; neuromuscular disease; randomized clinical trial; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis DeficienciesGeneral Medicineunfolded protein responseEndoplasmic Reticulum StressRiluzoleNeuroprotective AgentsNeurologyTolerabilityItalyDisease Progression1713GuanabenzMedical Futilitymedicine.drugmedicine.medical_specialtyamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies; Medicine (all)Neuroprotection03 medical and health sciencesmotor neurone diseaseDouble-Blind MethodInternal medicinemedicineHumansProteostasis Deficienciesbusiness.industryAmbientaleneuromuscular diseaserandomized clinical trialmedicine.diseaseClinical trial030104 developmental biologybusiness030217 neurology & neurosurgery
researchProduct

2017

Human neurodegenerative diseases are accompanied by accumulation of heavily oxidized and aggregated proteins. However, the exact molecular reason is not fully elucidated yet. Insufficient cellular protein quality control is thought to play an important role in accumulating covalently oxidized misfolded proteins. Pharmacologically active polyphenols and their derivatives exhibit potential for preventive and therapeutic purposes against protein aggregation during neurodegeneration. Although these compounds act on various biochemical pathways, their role in stabilizing the protein degradation machinery at different stages may be an attractive therapeutical strategy to halt the accumulation of …

0301 basic medicineOrganic ChemistryNeurodegenerationPharmaceutical ScienceProtein aggregationProtein degradationBiologymedicine.diseaseProtein oxidationAnalytical ChemistryCell biology03 medical and health sciences030104 developmental biologyChaperone-mediated autophagyProteostasisJUNQ and IPODBiochemistryProteasomeChemistry (miscellaneous)Drug DiscoverymedicineMolecular MedicinePhysical and Theoretical ChemistryMolecules
researchProduct

Cestode parasites release extracellular vesicles with microRNAs and immunodiagnostic protein cargo.

2017

Intercellular communication is crucial in multiple aspects of cell biology. This interaction can be mediated by several mechanisms including extracellular vesicle (EV) transfer. EV secretion by parasites has been reported in protozoans, trematodes and nematodes. Here we report that this mechanism is present in three different species of cestodes, Taenia crassiceps, Mesocestoides corti and Echinococcus multilocularis. To confirm this we determined, in vitro, the presence of EVs in culture supernatants by transmission electron microscopy. Interestingly, while T. crassiceps and M. corti metacestodes secrete membranous structures into the culture media, similar vesicles were observed in the int…

0301 basic medicineOtras Ciencias Biológicas030231 tropical medicineMesocestoides cortiPlatyhelminthCiencias Biológicas03 medical and health sciencesExtracellular Vesicles0302 clinical medicineTandem Mass SpectrometryAnimalsSecretionSecretionTaenia crassicepsbiologymicroRNATaeniaVesicleRNAExtracellular vesicleHelminth Proteinsbiology.organism_classificationIn vitroCell biologyEchinococcusMicroRNAs030104 developmental biologyInfectious DiseasesImmunologyTaeniaCestodaParasitologyExtracellular vesicleCestodeCIENCIAS NATURALES Y EXACTASIntracellularChromatography LiquidInternational journal for parasitology
researchProduct